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The major histocompatibility complex (MHC) 1 controls the expression of a variety 
of highly  polymorphic  cell  surface  antigens  that  play  important  roles  in  various 
aspects of the immune response (l-3). The class I molecules (human HLA-A, -B, and 
-C, and routine  H-2K,D and  L)  are  present  on all  nucleated cells and carry foreign 
determinants  important  in immune recognition by both alloantibodies  and alloreac- 
tire cytotoxic T  lymphocytes (CTL), and the self-determinants  important  in immune 
recognition of viralIy infected celIs by CTL. 
HLA-A, -B, and  -C antigens  are intrinsic  membrane glycoproteins composed of a 
polymorphic, MHC-encoded heavy chain of 44,000 mol wt, noncovalently associated 
with an invariant, non-MHC-encoded light chain of 12,000 mol wt, fi2 microglobulin 
(flzm)  (4).  Primary structural  studies have suggested that  the heavy chain consists of 
three  extracellular  domains  of  -90  amino  acids  each.  The  two  amino  terminal 
domains  are  polymorphic,  whereas  the  third  domain  is  relatively  nonpolymorphic. 
Both  fizm  and  the  third  extracellular  domain  display  sequence  homology  with 
immunoglobulin-constant  region domains. 
Multiple amino acid substitutions  distinguish even closely related allelic products; 
however, comparisons of a  limited  number amino acid sequences have indicated  the 
presence of three  or four more or less discrete  segments  of variability  (5).  It  is clear 
from  studies  of both  serologic  and  cellular  reactivities  that  multiple  allospecific 
recognition  determinants  exist  (1,  6-8).  However,  the locations of and  relationships 
among these determinants  have not been defined. 
The HLA-A2-specific mouse monoclonal antibody BBT.2  (9)  and complement has 
been  used  to  immunoselect  variant  clones  of the  B  lymphoblastoid  cell  line  TS-I 
(HLA-A1,  -A2,  -B8,  and  -B27)?  Three  major  classes  of variant  clones  have  been 
distinguished;  members  of two  classes  display  little  or no expression  of cell  surface 
HLA-A2 molecules.  In one case,  this  results  from an  apparent  failure  to synthesize 
HLA-A2 heavy chains, and  in the other case, although structurally altered  HLA-A2 
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heavy chains are synthesized, they associate with/~2m  inefficiently, if at all.  Previous 
studies  have demonstrated  that  mutant  HLA-A2 heavy chains that  fail  to associate 
with ~2rn  neither  mature  to the cell  surface nor express alloantigenic  determinants 
(10). 
Members of a third class ~.ppear to express normal amounts of cell-surface HLA-A2 
molecules that display reduced reactivity with the selecting antibody, but normal or 
near-normal reactivities with ~ome other HLA-A2-specific monoclonal antibodies and 
human alloantisera.  Such properties  indicated  their potential  utility in defining the 
BB7.2 epitope, as well as in probing the relationships  among various class I  antigen 
serologic and cellular recogniti~Jn determinants. 
Structural studies of the HLA-A2 heavy chains derived from two of these variants, 
8.18.1 and 8.21.1, are described in the present study. These variants are distinguishable 
both from TS-1  and  from each other by their relative reactivities  with  the selecting 
antibody  BB7.2,  as  well  as  with  a  second  HLA-A2-specific  rnonoclonal  antibody, 
PA2.1. In addition, HLA-A2 heavy chains synthesized by 8.18.1 are the equivalent of 
a single charge more basic than those of T5-1, whereas those synthesized by 8.21.1 are 
the equivalent  of a  single charge more acidic. 2 Comparative tryptic peptide analyses 
presented  here indicate that these heavy chains carry distinct  mutations in the same 
peptide.  We  conclude  that  residues  within  this  short  segment  of the  polypeptide 
contribute to an HLA-A2-specific serological determinant. 
Materials  and Methods 
Cell Lines and Metabolic Labeling.  The human  B lymphoblastoid cell  line T5-1  (HLA-A1, 
-A2, -BS, -B27, and -Cwl) and the HLA-A2 variant clones 8.18.1  and 8.21.1 derived from T5- 
1 by mutagenesis followed by immunoselection  2 were cultured as described (10). [4,5-3H]Lysine 
•  3  -  ,  3  ,  -  14  •  -  and  leucme,  [2,3-H]prohne  and  alanlne,  [G-H]serme,  the  respective  U-  C  amino  acids, 
3  -  •  35  •  •  35  •  -  -  [methyl-H]methlonme,  [  S]methlonme,  and  [  S]cysteme were  obtained  from  either  New 
England Nuclear, Boston, MA or ICN Chemical and Radioisotope Div., ICN Pharmaceuticals, 
Inc., Irvine, CA. Conditions for metabolic labeling were as described (1 t). 
Purification ofRadiolabeled HLA-A2 Heavy Chains.  This procedure has been described in detail 
elsewhere  (11). Briefly,  detergent lysates were prepared from labeled cells and immunoprecip- 
itated with the HLA-A2-specific mouse monoclonal antibody PA2.1  (12). After denaturation, 
immunoprecipitated species  were then subjected to a second round of immunoprecipitation, 
this time using a  rabbit  anti-HLA heavy chain serum  (13). The resulting HLA heavy chain 
preparations  were  of >95%  purity,  as  assessed  sodium  dodecyl  sulfate-polyacrylamide gel 
electrophoresis and fluorography. Yields of HLA-A2 heavy chain radioactivity as a percentage 
of total  incorporation into cells were typically 0.05%  for T5-1, half that  for 8.18.1,  and half 
again for 8.2 I. 1, because of reduced reactivities with the PA2.1 antibody. 
Peptide Mapping.  3H-, 14C-, or 35S-labeled HLA-A2 heavy chain preparations were combined, 
reduced and alkylated, and digested with trypsin as described  (11). Peptide mapping was by 
reverse-phase high-pressure liquid chromatography (HPLC) on a 4-ram ×  25-cm Zorbax C-8 
column (Dupont Instruments, Wilmington, DE), using a 0-30% concave gradient of acetonitrile 
in  10 mM ammonium acetate  (pH 6.5)  as described  (11).  Radioactivity was determined by 
liquid scintillation counting. 
Microsequence Analysis.  This  was  performed  on  a  Beckman  liquid-phase  sequencer  890C 
(.Beckman Instruments, Inc., Fullerton, CA) as described (11,  14). 
Results 
Strategy.  To assess the relatedness of the HLA-A2 heavy chains synthesized by the 
parent cell line T5-1 and its immunoselected variants, cells were metabolically labeled 326  STRUCTURE OF IMMUNOSELECT£D HLA-A2 MUTANTS 
with  either aH  or  14C  amino  acids,  and  purified  heavy chains  were compared  by 
double-label  tryptic peptide  analysis.  Crucial  to  such  an  analysis  is  the  ability to 
compare most,  if not  all,  tryptic peptides  in  the  molecule. 90% of the  amino  acid 
sequence of the 271  residue papain solubilized HLA A2 molecule (5),  as well as 32 
residues of the carboxy-terminal, intracetlular portion  have been  determined  (15). 
Thus, most  tryptic peptides can be predicted from the known sequence. Tentative 
assignments  for the remaining residues based upon homology with HLA-A28  (96% 
homologous) or with HLA-B7 (86%  homologous) when both HLA-A2 and -A28 are 
unassigned, predict 41 tryptic peptides. Although a combination of radioactive lysine 
and arginine should label all but the carboxy-terminal peptide, this approach could 
not be taken because of an inalaility to incorporate sufficient amounts of radiolabeled 
arginine.  The  alternative  adopted  involved metabolic  labeling  with  five different 
amino  acids,  which  would  label  overlapping sets  of tryptic peptides  encompassing 
virtually the entire molecule. The amino acids used, lysine (K), leucine (L), serine (S), 
proline (P), and alanine (A),  were predicted to label  11,  16,  11,  11, and  17 peptides, 
respectively, covering 98% of the detergent solubilized molecule. These numbers must 
be regarded with caution pending definitive assignment at the remaining residues of 
the HLA-A2 sequence. 
Previous work (1 I) has indicated that peptide mapping by reverse-phase HPLC is 
a  sensitive  method with  which  to compare most  tryptic peptides  in  the  molecule. 
Thus, in the present study, radiolabeled HLA-A2 heavy chains purified from parent 
and  variant  cell  lines  were  combined,  reduced  and  alkylated,  and  digested  with 
trypsin, and the resulting fragments were resolved and compared by HPLC. 
8.18. l.  Lysine-, leucine-, serine-, proline-, and alanine-containing tryptic peptides 
derived from T5-1 and 8.18.1  are compared in Figs. I-5, respectively. For the purpose 
of discussion, individual peaks will  be referred to based upon  the amino acid label 
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FIG.  3.  Serine-labeled tryptic peptides:  ['4CJserine-labeled T5-1  (-)  vs. [aH]serine-labeled 8.18.1 
(.  • .).  Differences that  are also evident  in the control  comparison  (Fig.  6)  are denoted  by solid 
arrows, whereas those unique to the experimental comparison are denoted by open arrows. Note 
that the solid arrow at tube S141 marks a shoulder sometimes, but not always resolved from that at 
S138 (see Fig. 8, for example). The factors influencing this resolution are not cell line specific. 
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FIG. 5.  Alanine-labeled tryptic  peptides:  [14C]alanine-labeled TS-1 (-)  vs.  [3H]alanine-labeled 
8.18.1  (-  •  -). 
and peak fraction number of the peptide.  Thus,  the flow-through peak in the serine 
map would be referred to as peak $6. It is immediately apparent that these molecules 
are highly homologous. No differences can be observed in  the  lysine-, leucine-,  pro- 
line-,  or  alanine-containing  tryptic  peptides.  However,  multiple  differences  in  the 
[aH]serine vs.  [14C]serine comparison are detected  (Fig. 3). KRANGEL  ET  AL.  329 
Differences in  the serine map  can  be grouped into two categories based  upon  a 
control  comparison  of [3H]serine  vs.  [14C]serine-labeled  T5-1  HLA-A2,  which  is 
presented in Fig. 6.  Thus, differences in Fig. 3 peaks $79, $82, S122, S130, and the 
shoulder at S141  (solid arrows) are also evident in the control comparison, whereas 
those in peaks S 126 and S 135 (open arrows) are not. Those differences present in the 
control comparison have been shown previously to result from the metabolic conver- 
sion of radiolabeled serine to  glycine with preferential loss  of 3H  label  during the 
interconversion (11).  This is the only interconversion that has been detected. 
Relative to the control comparison, the Fig. 3 comparison differs by the loss of 3H 
radioactivity at  peak  S126  and  the  gain  of 3H  radioactivity at  peak  S135.  This 
sugIgested  the  possibility that  TS-1  peptide S126 was  altered in  8.18.1,  and  hence 
ehlted later in the peptide profile, at S 135. This interpretation was confirmed and the 
difference peptide  was  identified  by the  following experiments.  Peptide  S126  was 
isolated from [3H]serine-labeled T5-1 HLA-A2 and subjected to 12 cycles of  automated 
Edman  degradation.  Radioactivity was released at cycle 8  (Fig.  7 A). Hydrolysis of 
the peptide followed by analysis by thin-layer chromatography indicated that virtually 
all of the radioactivity in  this  peptide migrated  as serine and  not  glycine; thus,  it 
could be concluded that S126 had a serine residue at position 8. Sequence analysis of 
peak S 135 from double-label comparisons of [3H]serine-labeled 8.18.1 and [t4C]serine- 
labeled  T5-I  HLA-A2  yielded  both  3H  and  1~C  radioactivity at  cycle  1,  and  3H 
radioactivity at cycle 8 (Figs.  7 B and C). We interpret this as a mixture of a peptide 
common  to  both  cell  lines  with  the  8.18.1  counterpart  of T5-1  peptide  S126.  A 
comparison of these partial  sequences with  those of all  predicted serine-containing 
tryptic peptides (Table I)  suggested that T5-1  peptide $126 spanned either residues 
98-108 or 244-256 in the HLA-A2 sequence, and that the T5-1 and 8.18.1 common 
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Fie.  7.  Microsequence  analysis of the  difference  peptide.  Appropriate  chromatogram fractions 
were subjected to automated Edman degradation as described in Materials and Methods. Radio- 
activity released in the chlorobutane extract at each cycle is presented. A represents the sequence of 
[aH]serine-labeled  T5-1  peptide  S126.  B  and  C  represent  the  corrected  aH  and  ~4C  channel 
radioactivities, respectively, for the sequence of 14C-labeled T5-1  and all-labeled 8.18. t  peptides at 
S135 from a  double-label comparison. D  represents the sequence of the [aSS]cysteine-labeled T5-1 
difference  peptide  at  fraction  126.  E  represents the  sequence of the  [aSS]cysteine-labeled  8.18,1 
difference peplide at fraction  135. 
peptide in peak S135  spanned residues  132-144.  Because the difference peptide was 
observed in neither the proline nor the alanine maps (Figs. 4 and 5, respectively), and 
because the peptide spanning residues 244-256 contains both of these residues (Table 
I), it was most likely that peptide S126 spanned residues 98-108 of the HLA-A2 heavy 
chain. 
Because identification of the difference peptide rested on the determination of only 
a  single  amino  acid,  further  partial  sequence  and  compositional  information  was 
desirable for confirmation. The sequence of the T5-1 form of this peptide is predicted 
to be MYGCDVGSDWR;  thus, it is unique in being the only tryptic peptide in the 
molecule that contains both methionine and cysteine. The presence of cysteine in the 
difference peptide was demonstrated by two lines of evidence. First, [14C]serine-labeled 
T5-1 HLA-A2 reduced and alkylated with iodoacetamide as usual was compared with 
[3H]serine-labeled T5-1  HLA-2 reduced and alkylated with iodoacetic acid. A differ- 
ence in such a comparison would identify an alkylated peptide, and this was indeed 
observed for peak S 126. Furthermore, separate peptide maps of [aSS]cysteine-labeled 
T5-1 HLA-A2 and 8.18.1  HLA-A2 were performed. A T5-1 peak at fraction  126 was 
absent in 8.18.1, and a new peak in 8.18.1  appeared at fraction 135. Sequence analysis KRANGEL ET AL.  331 
TABLE  I 
Serine-labeled To~ptic Peptides* 
Residue  number  Serine position(s)  Other residue(s) 
1-6  2, 4  -- 
7-14  5, 7  -- 
36-44  3, 7  Alanine 
83-97  6, 10  Alanine, leucine 
98-1o8~  8  - 
132-144§  1  Alanine, lysine 
187-202  9  Alanine, leucine 
244-256  8  Alanine, proline 
274-309[[  3, 4, 6  Alanine, proline, leucine 
312-315  1, 2 
317-338  3, 5, 9, 10, 12, 16, 19  Alanine, leucine 
* Data are derived from refs. 4, 5, and 15. 
M. S. Krangel, unpublished evidence for D102 and R108. 
§ By homology with HLA-A28 and -B7. 
II By homology with HLA-B7. 
of both  peaks  confirmed  the  presence  of cysteine  at  position  4  in  both  parent  and 
mutant  (Figs.  7 D  and  E).  A  double-label  comparison  using  [3H]methione  and 
[35S]methionine  demonstrated  a  similar  difference between  the  two cell  lines.  Thus, 
we conclude that a difference or differences in a single detectable peptide, that which 
spans  residues  98-108  in  the  HLA-A2  heavy  chain  sequence,  distinguishes  8.18.1 
HLA-A2 from the wild-type product. 
8.21.1.  Because variant 8.21.1 has properties similar, but not identical, to those of 
8.18.1,  it  was  of interest  to  determine  whether  it  carried  a  mutation  in  the  same 
peptide.  Thus  [14C]serine- and  [3H]serine-labeted  HLA-A2 heavy chain preparations 
from T5-1  and  8.21.1  were compared  by a  similar  analysis  (Fig.  8).  All of the  late- 
eluting peptides  are displaced by about  three fractions relative to previous compari- 
sons. The T5-1 glycine peptides at fractions  125,  133, and  144 (solid arrows)  are thus 
identical to Fig. 3 T5-1 peptides S121 and S130 and the shoulder at fraction 141, and 
the  T5-1  serine  peptides  at  fractions  129,  137,  and  141  are  identical  to Fig.  3  T5-1 
peptides S126, S134, and S138. It is clear from this comparison that the T5-1 peptide 
at  fraction  129  (open  arrow),  corresponding to S126  in  Fig.  3,  does  not  have a  co- 
migrating 8.21.1-derived counterpart. This indicates that 8.21.1 is altered in the same 
peptide  as  8.18.1.  However,  the  two  mutations  in  this  peptide  appeared  to  be 
nonidentical, because the 8.21.1 form of the peptide was not evident, eluting somewhat 
later than its T5-1 counterpart,  as was the 8.18.1  form. 
To clarify this  difference between  the two mutants,  it was of value to identify the 
8.21.1 form of the difference peptide. It might not be observed in the Fig. 8 comparison 
because of altered solubility properties, poor elution off the column, the loss of a serine 
residue at position 8, or co-elution with higher-yield peptides.  Some of these possibil- 
ities  could  be  tested  by  choosing  a  different  amino  acid  for  labeling  the  peptide; 
methionine was an optimal choice because it is a relatively rare amino acid that labels 
the corresponding T5-1  peptide.  A  comparison of [3H]methionine- with  [35S]methio- 
nine-labeled peptides is presented in Fig. 9. The two cell lines clearly differ in that the 
T5-1  peptide  at  M126  has  apparently  shifted  to M88 in 8.21.1  (open arrows).  This 332  STRUCTURE OF  IMMUNOSELECTED HLA-A2  MUTANTS 
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corresponds  to  a  cluster  of peaks  in  the  serine  map,  within  which  the  [aH]serine- 
labeled 8.21. i  difference peptide would  have gone undetected.  We cannot,  from  this 
analysis,  eliminate  the  possibility  of  a  loss  of  serine  from  this  peptide,  however. 
Additional experiments comparing in parallel [aSS]cysteine-labeled peptides from T5- KRANGEL ET AL.  333 
1 and 8.21.1  yielded results consistent with those of the methionine-containing peptide 
comparison. 
Discussion 
HLA-A2 mutants  have  been  obtained  by  immunoselection  using  the  HLA-A2- 
specific  mouse  monoclonal  antibody  BB7.2  plus  complement.  Two  mutants  that 
synthesize HLA-A2 molecules with reduced reactivity with the selecting antibody and 
with structurally altered  HLA-A2 heavy chains have been analyzed in detail.  Using 
double-label tryptic peptide mapping, we demonstrate that these two mutants have 
distinct alterations in the same tryptic peptide in the molecule. Although it is possible 
that  other  alterations  in  these  molecules  exist  but  have  not  been  detected  by the 
present  analysis,  the  isolation of two mutants  with  alterations  in  the  same peptide 
suggests  strongly  that  the  detected  changes  play  crucial  roles  in  determining  the 
serologic properties of these molecules. 
Available  evidence  suggests  that  the  mutations  do  not  induce  gross  structural 
alterations  in  these  molecules.  Thus,  although  reactivities  with  both  the  selecting 
antibody  and  the  HLA-A2-specific  monoclonal  antibody  PA2.1  are  diminished, 
reactivities  with  a  polyclonal  HLA-A2-specific human  alloantiserum  are  largely 
unaffected, and no effect at all has been observed with respect to the binding of the 
HLA-A2 and  -B17-specific monoclonal antibody MA2.1  (16)  and  the  HLA-A, -B, 
and  -C-specific monoclonal antibody W6/32. 2 The determinants  recognized by all 
such antibodies are highly sensitive to the conformation of the molecule. Furthermore, 
although the altered peptide is known to contain a  cysteine involved in an intramo- 
lecular  disulfide  bond,  the  results  of labelings  with  [35S]cysteine  indicate  that  this 
residue  has  not  changed  in  either  mutant.  It  is  therefore  likely  that  a  residue  or 
residues  in  this peptide  play a  direct  role in  forming an  HLA-A2-specific antigenic 
determinant. 
Comparative primary structural  analyses of three HLA molecules have indicated 
the presence of a  few discrete segments that  display relatively high variability,  the 
most prominent of which span residues 65-80,  105-116, and  177-194. HLA-A2 and 
-A28 are highly cross-reactive, and only 10 amino acid differences have been detected 
between  them  (5). Five  are  in  the  first  segment,  two  are  in  the  second,  and  the 
remainder  are  highly conservative substitutions  scattered  throughout the molecule. 
The  difference  peptide  defined  in  this  study  spans  residues  98-108  and  has  the 
sequence MYGCDVGSDWR. HLA-A28 has an identical sequence, save for a  W  to 
G  substitution  at position  107. Because the monoclona[ antibody used for immuno- 
selection reacts with HLA-A2 but not with HLA-A28, some of the residues that form 
the BB7.2 epitope should differ in HLA-A28. We suggest that W107 may therefore be 
a  critical  residue  in  forming the  BB7.2 antigenic determinant.  Although we do not 
know which residues  are altered  in  mutants 8.18.1  and  8.21.1,  we nevertheless can 
hazard a guess. The 8.18.1  HLA-A2 heavy chain is a single charge more basic than its 
wild-type counterpart, and the difference peptide has elution properties that indicate 
an  increase  in  hydrophobicity.  These  and  other  pieces  of  evidence  suggest  the 
likelihood of a  substitution of a  neutral amino acid for an acidic one. Although two 
acidic residues exist in the wild-type form of the peptide, we suggest that D 106, which 
is within the previously defined variable segment and adjacent  to W107, may have 
changed in  8.18.1.  Conversely, because the  8.21.1  HLA-A2 heavy chain  is  a  single 334  STRUCTURE  OF  IMMUNOSELECTED HLA-A2 MUTANTS 
charge more acidic than wild type, and the difference peptide in this case appears less 
hydrophobic, the substitution here may involve the gain of an acidic residue. 
Although  residues in this peptide are necessary for the complete expression of the 
BB7.2 and  PA2.1  epitopes, they are certainly not sufficient.  Neither antibody binds 
detectably to wild-type HLA-A2 heavy chains that are not associated with fl2m (13; 
P.  Parham,  personal  communication),  presumably  because  of  the  loss  of  native 
conformation  (17).  Furthermore,  preliminary  results  indicate  that  a  third  BB7.2- 
immunoselected mutant,  8.6.1,  has  an  alteration  in  a  peptide  distant  in  the  linear 
amino acid sequence from that described here, but nevertheless residing in the same 
domain of the HLA-A2 heavy chain  (S.  Taketani and  M.  S.  Krangel, unpublished 
observations).  Thus,  other segments of the  polypeptide in  the  second  domain  may 
take  part  directly  in  the  BB7.2  epitope,  or  possibly  stabilize  the  conformation  of 
residues that are directly involved. 
Histocompatibility antigens  carry multiple serologically defined alloantigenic de- 
terminants.  Blocking studies  in  both  the  murine  and  human  systems have demon- 
strated the presence of spatially separate antibody binding sites on the same molecule 
(18-20).  Although  BB7.2,  PA2.1,  and  MA2.1  all  cross-block  (8,  9),  their  antigenic 
determinants  are nevertheless  distinct.  The  MA2.1  determinant  is  clearly different 
from those of PA2.1  and BB7.2  because it  is also found on HLA-B17, and because 
mutants selected with  BB7.2  are unaltered  in  their MA2.1  reactivity. On  the other 
hand, the determinants recognized by BB7.2 and PA2.1 are nearly identical. Although 
neither antibody reacts with HLA-A28, both react with a presumed HLA-A28 variant 
cell line, IDF, and immunoselection ofT5-1  HLA-A2 mutants with BB7.2 results in 
an  altered  PA2.1  determinant.  However, the  different  mutations  that  characterize 
8.18.1  and 8.21.1  can distinguish these antibodies. Thus, comparative binding studies 
indicate  that  whereas  PA2.1  has  a  higher  affinity  for  8.18.1  than  for  8.21.1,  this 
situation  is  reversed  for  BB7.2  (unpublished  observations).  The  binding  of these 
antibodies  to HLA-A2 molecules may involve different  contacts, possibly including 
some different residues, at the same site on the molecule. 
Increasing evidence indicates that the determinants defined by serology may not be 
identical with those recognized by CTL. Thus, H-2K  b mutants with gross alterations 
in CTL recognition properties have rather limited alterations in serological determi- 
nants  (21,  22).  HLA-A2  structural  variants  that  are  not  recognized  by  HLA-A2- 
restricted, influenza-virus-immune or HLA-A2-specific alloimmune CTL nevertheless 
have  normal  reactivities  with  alloantisera  and  monoclonal  antibodies  specific  for 
HLA-A2 (11, 23, 24). 3 Preliminary results indicate HLA-A2-specific alloimmune CTL 
recognition  of immunoselected mutants  8.18.1,  8.21.1,  and  8.6.1  may be largely or 
completely unaffected  (C. Ware, personal communication).  However, detailed anal- 
yses of the reactivities of a battery of HLA-A2-specific CTL clones will be required to 
more precisely address this question. It is anticipated that extensive primary structural 
comparisons of allelic products,  the generation and analysis of many other variants 
with  altered  recognition  properties,  and  ultimately,  knowledge of the three-dimen- 
sional structure of the molecule should allow a precise understanding of the relation- 
ships among these various determinants on the surface of the molecule. 
3 Krangel,  M.  S.,  W.  E.  Biddison,  and J.  L.  Strominger.  1983. Comparative structural 
analysis  of HLA-A2 antigen  distinguishable by cytotoxic T  lymphocytes. II. Variant  DKI: 
evidence for a discrete CTL recognition  region. J. hnmunol. In press. KRANGEL ET  AL.  335 
Summary 
The  HLA-A2-specific mouse  monoclonal  antibody  BB7.2  plus  complement  has 
been used to immunoselect variant clones of the lymphoblastoid cell line T5-1  (HLA- 
A1, -A2, -Bg, and -B27). Members of one class of variant clones appear to express cell 
surface HLA-A2 molecules that display reduced reactivity with the selecting antibody, 
but normal or near normal reactivities with some other HLA-A2-specific monoclonal 
antibodies and human  alloantisera. The HLA-A2 heavy chains derived from two of 
these variant clones were characterized by comparative double-label tryptic peptide 
mapping in conjunction with microsequence analysis. These heavy chains were found 
to carry distinct mutations  in  the same peptide in  the molecule. We conclude that 
residues  within  this  short  segment  of the  polypeptide contribute  to  an  HLA-A2- 
specific serological determinant. 
We would like to thank Bill Lane for expert technical assistance, Alan Korman  for critical 
comments on the manuscript, and Cindy Lehn for typing the manuscript. 
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